Skip to main navigation Skip to search Skip to main content

Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study

  • Floris Jan Voskuil
  • , Steven Jakob de Jongh
  • , Wouter Tjerk Rudolph Hooghiemstra
  • , Matthijs David Linssen
  • , Pieter Jan Steinkamp
  • , Sebastiaan Antonius Hendrik Johannes de Visscher
  • , Kees-Pieter Schepman
  • , Sjoerd Geert Elias
  • , Gert-Jan Meersma
  • , Pascal Klaas Christiaan Jonker
  • , Jan Johannes Doff
  • , Annelies Jorritsma-Smit
  • , Wouter Bastiaan Nagengast
  • , Bert van der Vegt
  • , Dominic James Robinson
  • , Gooitzen Michell van Dam
  • , Max Johannes Hendrikus Witjes

Research output: Contribution to journal › Article › Academic › peer-review

8 Downloads (Pure)

Abstract

Tumor-positive resection margins are present in up to 23% of head and neck cancer (HNC) surgeries, as intraoperative techniques for real-time evaluation of the resection margins are lacking. In this study, we investigated the safety and potential clinical value of fluorescence-guided imaging (FGI) for resection margin evaluation in HNC patients. We determined the optimal cetuximab-800CW dose by quantification of intrinsic fluorescence values using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy. Methods: Five cohorts of three HNC patients received cetuximab-800CW systemically: three single dose cohorts (10, 25, 50 mg) and two cohorts pre-dosed with 75 mg unlabeled cetuximab (15 or 25 mg). Fluorescence visualization and MDSFR/SFF spectroscopy quantification was performed and were correlated to histopathology. Results: There were no study-related adverse events higher than Common Terminology Criteria for Adverse Events grade-II. Quantification of intrinsic fluorescence values showed a dose-dependent increase in background fluorescence in the single dose cohorts (p<0.001, p<0.001), which remained consistently low in the pre-dosed cohorts (p=0.6808). Resection margin status was evaluated with a sensitivity of 100% (4/4 tumor-positive margins) and specificity of 91% (10/11 tumor-negative margins). Conclusion: A pre-dose of 75 mg unlabeled cetuximab followed by 15 mg cetuximab-800CW was considered the optimal dose based on safety, fluorescence visualization and quantification of intrinsic fluorescence values. We were able to use a lower dose cetuximab-800CW than previously described, while remaining a high sensitivity for tumor detection due to application of equipment optimized for IRDye800CW detection, which was validated by quantification of intrinsic fluorescence values.

Original languageEnglish
Pages (from-to)3994-4005
Number of pages12
JournalTheranostics
Volume10
Issue number9
DOIs
Publication statusPublished - 2020

Keywords

  • Cetuximab-800CW
  • Fluorescence-guided imaging
  • Head
  • Intrinsic fluorescence
  • MDSFR/SFF spectroscopy
  • Neck cancer

Fingerprint

Dive into the research topics of 'Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study'. Together they form a unique fingerprint.

Cite this